Turmeric Oil Compounds Inhibit Amyloid Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive decline and Alzheimer's disease, particularly those targeting beta-secretase, have shown limited efficacy, and there is a need for stable, biologically effective compounds derived from natural sources to inhibit amyloid production and aggregation.
Innovation Solution
The development of chemically conditioned compounds from turmeric oil, specifically those with Formula I-0, I-1, and I-2, which are chemically stable and structurally diverse, for use in pharmaceutical compositions to inhibit amyloid production, aggregation, and the activity of Abeta oligomers, thereby treating cognitive decline and Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current beta-secretase targeting treatments are used, then cognitive decline and Alzheimer's disease are addressed, but limited efficacy is achieved
Solution Approach 1:
The patent modifies the chemical structure of curcuminoid compounds through chemical conditioning processes, creating derivatives with improved stability and enhanced biological activity. This structural parameter change resolves the contradiction by maintaining the core therapeutic function while achieving superior efficacy compared to natural curcuminoids.
Solution Approach 2:
The invention creates composite chemical structures by combining curcuminoid backbones with modified side chains and functional groups. These composite compounds integrate the benefits of natural product recognition with synthetic enhancement, achieving both reliability and adaptability in treating Alzheimer's disease.
2Reliability
If natural curcuminoids are used, then amyloid production and aggregation are inhibited, but chemical instability occurs
Solution Approach 1:
The patent systematically modifies physical and chemical parameters of curcuminoids including oxidation states, substitution patterns, and molecular weight. These parameter changes produce compounds that retain amyloid-inhibiting biological activity while achieving enhanced chemical stability through reduced susceptibility to degradation.
Solution Approach 2:
The chemical conditioning process extracts and isolates the active curcuminoid core structure while removing or modifying unstable functional groups. This extraction approach separates the essential biological activity from the sources of chemical instability, resolving the contradiction between efficacy and stability.
3Adaptability or versatility
If structurally diverse compounds are created, then drug screening candidates are improved, but manufacturing complexity increases
Solution Approach 1:
The patent divides the curcuminoid molecule into modular segments: a stable core diketone structure and variable side chain components. This segmentation allows independent optimization of each module and facilitates systematic synthesis of diverse derivatives through combinatorial chemistry, reducing overall manufacturing complexity.
Solution Approach 2:
The invention develops a universal chemical conditioning platform that can transform various curcuminoid substrates into active derivatives using standardized reaction protocols. This multi-functional approach enables diverse compound production through a single versatile methodology, minimizing synthesis complexity while maximizing structural diversity.
Data Source
Figure 1A~1D
Figure 2A~2D
Figure 3
AI summary
Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods for treatment, inhibition, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.